Book Online or Call 1-855-SAUSALITO
Sign In \| Register \| About Sausalito \| Contact Us
Sausalito, CA September 01, 2020 1:41pm 7-Day Forecast \| Traffic

- Apartments

Search Hotels in Sausalito
CHECK-IN:
CHECK-OUT:
ROOMS:

Find A Business
or Browse Listings

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

181.46 -1.95 (-1.06%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

March 19, 2026

From Biogen Inc.

Via GlobeNewswire

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗

February 08, 2026

Via Stocktwits

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

March 11, 2026

From Biogen Inc.

Via GlobeNewswire

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...

Via StockStory

Topics Artificial Intelligence

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

March 05, 2026

From Biogen Inc.

Via GlobeNewswire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Biogen Inc.

Via GlobeNewswire

3 Value Stocks Walking a Fine Line

February 18, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call

February 13, 2026

Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales....

Via StockStory

Topics Earnings

February 12, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

Biogen Announces Board Chair Transition

February 11, 2026

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair

From Biogen Inc.

Via GlobeNewswire

BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds

February 07, 2026

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share...

Via StockStory

Why Biogen Stock Surged Almost 9% Higher on Friday ↗

February 06, 2026

It's obvious that the company has a good shot at returning to growth.

Via The Motley Fool

What's going on in today's session: S&P500 movers ↗

February 06, 2026

Via Chartmill

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

Biogen (BIIB) Q4 2025 Earnings Call Transcript ↗

February 06, 2026

Biogen (BIIB) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

February 06, 2026

As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based...

Via Finterra

Topics Earnings Economy Intellectual Property

Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales

February 06, 2026

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results topping the market’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share...

Via StockStory

Topics Artificial Intelligence

Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 04, 2026

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Friday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence World Trade

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

February 04, 2026

Via Chartmill

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

February 04, 2026

From Biogen Inc.

Via GlobeNewswire

1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

February 02, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

January 28, 2026

From Biogen Inc.

Via GlobeNewswire

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗

January 20, 2026

Via MarketBeat

Which S&P500 stocks are gapping on Wednesday? ↗

January 14, 2026

Via Chartmill

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

January 12, 2026

From Biogen Inc.

Via GlobeNewswire

3 Reasons to Sell BIIB and 1 Stock to Buy Instead

January 11, 2026

The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid...

Via StockStory

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Via PredictStreet

Topics Earnings Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Search Hotels in Sausalito

Find A Business

or Browse Listings

Biogen Idec (NQ:BIIB)

All News about Biogen Idec